UPLOAD Filing
Akari Therapeutics Plc
Date: May 9, 2025 · CIK: 0001541157 · Accession: 0000000000-25-004988
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287012
Letter
Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed May 6, 2025 File No. 333-287012 Dear Abizer Gaslightwala:
May 9, 2025
Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Sam Zucker, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 9, 2025 Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed May 6, 2025 File No. 333-287012 Dear Abizer Gaslightwala: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sam Zucker, Esq. </TEXT> </DOCUMENT>